1



# 2025 SSDI/Grade

Melissa Riddle, ODS-C


Iowa Cancer Registry Annual Updates

April 2025

SSDI v3.2

#### • Current SSDI Manual is found on the NAACCR website:

https://apps.naaccr.org/ssdi/list/?\_gl=1\*os2bpr\*\_ga\*NDk5ODY0NziBLjE3MzE5NDlwMTA.\*\_ga\_ V7J8GWYK5P\*MTc0MzcwNzQyMS45NI4wLjE3NDM3MDc0MjEuNjAuMC4w\_



#### information. This data items records the low axillary (level I and intramammary) and mid-axillary (level II, also called interpectora This data item excludes level III (high axillary, also called apical or infractavicular), internal mammary and supractavicu Do not confuse intramammary nodes, which are within breast tissue and are included in level I, with internal mamma This field is based on pathological examination of ipsilateral (same side as the primary cancer) level I and II axillary by is included even if the patient had neoadjuvant therapy prior to lymph node removal. Do not include lymph nodes containing only isolated tumor cells (ITCs-metastases less than 0.2 mm in size) in the o Rationale Lymph Nodes Positive Axillary Level I-II can be collected by the surveillance community for breast cancers. Prior to 20 Nodes Positive Axillary Level I-II. Additional Info Required for Staging: EOD only. Source documents: pathology report Notes Note 1: Physician Statement > Physician statement of number of positive ipsilateral Level I-II axillary nodes can be used to code this data item, v available. Note 2: Axillary Level I and II lymph nodes

This data item pertains to the number of positive ipsilateral level I and II axillary lymph nodes and intramammary lym

Include only the number of positive ipsilateral level I and II axillary lymph nodes and intramammary lymph nodes located within the breast, are not the same as internal mammary nodes, located along the sternum.

### General Instruction Updates

• Alignment between SEER\*RSA and SSDI manual

4

- V3.2 in SEER\*RSA and SSDI will now have the same information
- Notes
  - Reformatted each note will have a short header
  - Many SSDI formats were changed but NOT the content and not included in change log

3

Description



PTLD

## **NEW SSDI**

### • Lung – PD-L1

- Effective for cases diagnosed 2025+
- Physician statement can be used if no other information
- Primary Source: Pathology Report or Lung Biomarker Report
  - **Document the tumor proportion score** (0.0-100.0)
  - Actual score takes priority over:
    - XXX.2 stated as negative
    - XXX.3 stated as low
    - XXX.4 stated as positive
- Neoadjuvant Therapy:
  - If administered report assay from tumor specimen prior to neoadjuvant tx
  - · If there is no pre-treatment results report the post-treatment findings

# PD-L1 Codes

Description	Code
No PD-L1 expression; Tumor Proportion score = 0%	0.0
0.1-100.0 PD-L1 expression; Tumor Proportion score = 0.1%-100.0%	0.1 - 100.0
PD-L1 expression absent AND Tumor Proportion score stated negative	XXX.2
PD-L1 expression present AND Tumor Proportion score stated as low	XXX.3
PD-L1 expression present AND Tumor Proportion score stated as high/positive	XXX.4
Test ordered, results not in chart	XXX.7
Not documented in the record; No microscopic confirmation of tumor; PD-L1 can't be determined, not assessed, or unknown if assessed	XXX.9

# **NEW SSDI**

- Post Transplant Lymphoproliferative Disorder (PTLD)
  - Applies to schemas:
    - 00790 Lymphoma
    - 00795 Lymphoma CLL/SLL
    - 00812 Primary Cutaneous Lymphomas (exclude Mycosis Fungoides)
    - 00821 Plasma Cell Myeloma
    - 00822 Plasma Cell Disorders
  - Effective 2025+


7

# Types of PTLD

#### Polymorphic PTLD

- PTLD by itself, no accompanying lymphoma, plasmacytoma, or other type of Hematopoietic neoplasm
- This type is <u>NOT</u> collected as an SSDI
- This is a reportable cancer 9971/3 (2025+)
- Monomorphic PTLD 🖈
  - Most common and is associated with a malignant hematopoietic neoplasm
     Most common, but not limited to, DLBCL and Burkitt lymphoma
- Classic Hodgkin lymphoma-PTLD type
  - Reed-Sternberg cells which are associated w/ Hodgkin Lymphoma are present
- PTLD, NOS ★
  - Used when only PTLD is documented and there is no mention of monomorphic or Hodgkin like type
  - Also used for Burkitt-like PTLD

### **PTLD Coding**



# **PTLD - Examples**

### Example 1

Path report: staining supports the diagnosis of PTLD, monomorphic type, EBV+ diffuse large b-cell lymphoma (non-germinal center)

#### Histology:

9680/3

#### SSDI - PTLD:

1

#### Example 2

Right inguinal LN biopsy: CD20+ polymorphic PTLD


9

#### Histology:

9971/3

#### SSDI – PTLD:

N/A



# Schema Changes - Updates

Site	Schema	Applicable Years	Notes
	00360	2018-2024	
Lung	09360	2025+	AJCC lung v9 Histology 8982 (Myoepithelioma carcinoma) <b>ADDED</b>
Nasopharynx	00090	2018-2024	
	09090	2025+	AJCC Nasopharynx v9
Pleura Mesothelioma	00370	2018-2024	
	09370	2025+	AJCC Pleura Mesothelioma v9
Thymus	00350	2018-2024	
	09350	2025+	AJCC Thymus v9 Histology 8980 (Carcinosarcoma) <b>ADDED</b>
Soft Tissue Abdomen/Thoracic	00421	2025+	Primary Site C340-C349, histology <i>8982 removed</i> Pimary Site C379, histology <i>8980 removed</i>

# Changes to Current SSDIs

### Brain v9

- Coding Guidelines:
  - NEW Note:
    - Code 86 for benign (/0) or borderline (/1) tumor
      - Includes microscopic or non-microscopic confirmed cases
      - **EXCEPTION**:
        - Histology 9421/1
          - See codes 19 & 20 when microscopic confirmed
          - If 19-20 don't apply or not microscopically confirmed code 99

### Prostate

### • Number of Cores Positive/Examined

- Note 2: Priority Order
  - Final Diagnosis
    - If the core biopsy path report contains a summary of the number of cores positive use the summary provided
    - Do NOT include cores of other areas like seminal vesicles
  - Gross Description
    - Can be used to code this data item when the final diagnosis is not available and gross provides the actual number of cores and not pieces, chips, fragments, etc.
  - Physician Statement (see Note 1)

15

### Prostate – NEW Notes

#### Gleason Patterns Pathological

#### Note 7: Active Surveillance, then Radical Prostatectomy

• **Code X9** when first course treatment is active surveillance, but a radical prostatectomy is done later due to dz progression or patient changed their mind

### • Gleason Score Pathological and Gleason Tertiary Pattern

#### Note 5: Active Surveillance, then Radical Prostatectomy

Code X9 when first course treatment is active surveillance, but a radical
prostatectomy is done later due to dz progression or patient changed their mind

Other Updates:

### Colon/Rectum

- BRAF Mutational Analysis
  - New Code 3
    - Abnormal (mutated)/detected, KIAA549-BRAF

#### Lung

- Visceral and Parietal Pleura Invasion
  - Note 2: Criteria for Coding
    - EXCEPTION:
      - In situ tumors (/2) can be coded 0 based on biopsy or surgical resection

17

/


/

# Other Updates:


### Melanoma Skin

- Clinical Margin Width:
  - If a range is listed, code the lower range
    - Example: Clinical margin width documted as 1-1.2cm, code 1cm


- Melanoma Iris, Choroid, and Ciliary Body
  - Chromosome 3 status
    - Added: Loss of BAP1 expression




# Clinical & Path Grade Coding Timeframe



### Post-Therapy Grade Coding Timeframe





**NEW Table** 

Pleural Mesothelioma Table 27 (2025+)

Grade Description	Code
Nuclear Grade 1 WITH or WITHOUT necrosis <b>OR</b> Nuclear Grade 2 WITHOUT necrosis	L
Nuclear Grade 2 WITH necrosis <b>OR</b> Nuclear Grade 3 WITH or WITHOUT necrosis	н
Grade cannot be assessed; Unknown	9

23

23

## Breast – Grade Table 12

Timeframe	Note	Description
Post-Therapy Clinical (yc)	Note 4	<ul> <li>2 Major grading systems used for breast and based on behavior:</li> <li>Invasive: Nottingham grade/score</li> </ul>
Post-Therapy Path (yp)	Note 5	<ul> <li>Based on 3 components: tubule formulation, nuclear pleomorphism, and mitotic count</li> </ul>
Post-Therapy Clinical (yc)	Note 6	"Grade 1, 2, or 3" stated for invasive cancer and <b>NO</b> further information, assume this is the Nottingham grade
Post-Therapy Path (yp)	Note 7	<ul> <li>"Well diff, Mod diff, Poorly diff, Iow, med, high" use grades Generic Grade Categories A-D</li> <li>Do NOT use L, M, or H for invasive tumors</li> </ul>
Post-Therapy Clinical (yc)	Note 6	<ul> <li>In Situ tumors the preferred grading system is based on a 3 grade Nuclear system:</li> <li>Low (L) (Nuclear grade 1)</li> <li>Intermediate (M) (Nuclear grade 2)</li> </ul>
Post-Therapy Path (yp)	Note 8	<ul> <li>High (H) (Nuclear grade 3)</li> <li>If pathologist states Nottingham grade for in-situ tumor they are documenting the nuclear grade – code L, M, or H</li> <li>Do NOT use grades 1, 2, or 3 for in situ tumors</li> </ul>



# Other Updates...

### • Appendix – Table 06

- Clinical; Grade Post-Therapy Clinical = Note 4
- Pathological; Grade Post-Therapy Path = Note 5
  - Assign Grade 1 for LAMN tumors
  - Assign Grade 2 for HAMN tumors Note: This was confirmed by AJCC physician experts
- Cervix Sarcoma/Corpus Carcinoma & Carcinosarcoma/Corpus Sarcoma – Table 13
  - Clinical; Grade Post-Therapy Clinical = Note 3
  - Pathological; Grade Post-Therapy Path = Note 4
    - For endometroid carcinomas ONLY
      - "Low grade" = code 2 (FIGO Grade 2)
      - "High grade" = code 3 (FIGO Grade 3)



## Lung SSDI

Biomarker	Method	Analyte	Result	Therapeutic Assoc
PD-L1 (22c3)	IHC	Protein 🤇	Positive, TPS: 10%	Benefit – prembrolizumab
PD-L1 (28-8)	IHC	Protein	Positive, 1+, 5%	Benefit – nivolumab/Ipilimumab combo
PD-L1 (SP263)	IHC	Protein	Positive, TC: 1+ 10%	Benefit – atezolizumab (adjuvant)

### What is the correct code for this lung cancer PD-L1 SSDI?

Code: 10.0
We code based on the Tumor
Proportion Score (TPS)

Note 4: Tumor Proportion Score

- PD-L1 is documented by the tumor proportion score. Record the actual Tumor Proportion Score (0.0-100.0) as stated from the pathology report.
- An actual tumor proportion score (.1-100.0) takes priority over XXX.2 (Stated as negative), XXX.3 (Stated as low), or XXX.4 (Stated as high/positive)

27

# Lung SSDI

Results from a PD-L1 report: PD-L1 IHC 22C3 pharmDX – Tumor Proportion Score (TPS)\*: <1% Expression level: Negative for PD-L1 expression (TPS less than 1%)

### What is the correct code this lung cancer PD-L1 SSDI?


Code: 0.9 Based on general instructions recording values when "less than" are used SSDI Manual, pg. 22

Recording values when "less than," "greater than," and "or least" are used

Record the value as **one less** than stated when a value is reported as "less than X," and as **one more** than stated when a value is reported as "more than X" or "at least." **One less** or **one more** may refer to a whole number (1), or a decimal (0.1), depending on the code structure of the field.

### PTLD

Bone Marrow biopsy: monomorphic post-transplant lymphoproliferative disorder (plasma cell myeloma), EBV negative. Monoclonal kappa plasmacytosis (estimated 20% by CD138 IHC)



29

## PTLD

Per physician, Stage IIA (bulk) PTLD – Hodgkin-like morphology, intermediate risk

What is the correct histology?

**9650/3** Classic Hodgkin Lymphoma

### How would you code SSDI PTLD?



### **Brain Molecular Marker**

Cerebellar vermis resection: Pilocytic astrocytoma, CNS WHO grade 1; ngs: p.Gln22Lys and p.Leu19Phe in KRAS gene; Negative MYB, MYBL1

Physician note: KRAS Q22K and L19F mutations are not common for this type of tumor but do involve the pathway that is often altered for pilocytic astrocytoma. The genetic alteration does not change the plan for imaging surveillance.

#### How should we code Brain Molecular Marker?

- A. 19 Diffuse astrocytoma, MYB or MYBL1 altered
- B. 86 Borderline/Benign tumor
- C. 99 Not documented in medical record; unknown



31

# **Breast Grade**

Right UOQ breast, breast: DCIS, Nottingham Grade 2 Right UOQ, lumpectomy: Invasive ductal carcinoma, poorly differentiated

### What is the clinical grade?


 M – DCIS Nott Grade 2
 You can't use codes 1, 2, or 3 for in situ tumors
 Note 7: if Nottingham grade is stating the nuclear grade and code L, M, or H appropriately

### What is the pathological grade?

**C** – IDC, Poorly Diff **Note 6**: For invasive tumors use Generic Grades A-D as appropriate when it uses the "differentiation" for grade

## **Endometrioid Grade**

Endometrium biopsy: low grade endometrioid carcinoma TAH/BSO: endometrioid carcinoma, FIGO grade 1



33



# Questions?

Contact: Melissa Riddle, ODS-C melissa-riddle@uiowa.edu